NEWS Release

Regulatory Approval for an Open Label Clinical Trial

Date: April 13, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. ("Wex" or the "Company") is pleased to announce that it received regulatory approval (No Objection Letter) from Health Canada, on April 8, 2004, for initiating an Open-Label extension Clinical Trial for Tectin™ in patients with moderate to severe cancer-related pain. This multi-centre, safety and efficacy study is a long-term continuation of the current Pivotal Phase IIb/III trial that is underway and will be run in parallel.

In an effort to enforce Wex's commitment to improving quality of life the Company requested this study in order to make Tectin™ available to all patients who participate in the Pivotal Phase IIb/III trial. This will allow the patients who obtained benefit from the drug as well as those who received placebo to obtain Tectin™ for continued t reatment while providing the Company with data on the long-term safety and efficacy of the product. This would preclude preventing or delaying patients benefiting from continued treatment before product commercialization.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.